How should we manage a 77‑year‑old woman with a recent cryptogenic cerebral infarct, a 4‑mm anterior communicating artery aneurysm, chronic coronary artery disease status post coronary artery bypass grafting, approximately 23 % left‑ventricular scar with ejection fraction 40‑45 %, presenting with a type‑2 non‑ST‑segment elevation myocardial infarction, while respecting her palliation goals and do‑not‑resuscitate status?

Management of Type 2 NSTEMI in a 77-Year-Old Woman with Cryptogenic Stroke, Cerebral Aneurysm, and Palliative Goals

Given this patient's DNR/I status, palliative goals, 23% LV scar burden deemed non-revascularizable, and type 2 NSTEMI, conservative medical management without invasive coronary intervention is the appropriate strategy, focusing on supportive care, biomarker surveillance, and optimized secondary prevention. 1

Rationale for Conservative Management

This patient's type 2 MI—caused by supply-demand mismatch rather than acute coronary thrombosis—does not benefit from invasive revascularization in the same manner as type 1 MI 1. The 2025 ACC/AHA guidelines clearly distinguish type 2 MI as resulting from oxygen supply-demand imbalance unrelated to acute coronary atherothrombosis 1. Combined with her:

• Explicit palliative goals and DNR/I status precluding invasive procedures
• 23% LV scar with EF 40-45% previously deemed non-recoverable with revascularization
• Prior determination in recent years that she was not a candidate for LAD intervention due to scar burden and viability
• Stable ECG without ongoing ischemia (transient chest pain yesterday, now resolved)

The decision against catheterization is both medically sound and aligned with her stated preferences.

Cardiac Management Algorithm

Immediate Actions (First 24 Hours)

Biomarker Surveillance:

• Continue troponin cycling every 6 hours until peak is identified and downtrending 1
• Peak troponin levels provide prognostic information for risk stratification 2
• Current values (1,712 → 1,396 → 1,539 → 800 ng/L) suggest possible peaking

Hemodynamic Optimization:

• Lasix 20mg IV as ordered for decompensated HFrEF (rales noted on exam)
• Monitor response to diuresis given reduced EF (42.7%) and grade 2 diastolic dysfunction
• Continue telemetry monitoring for arrhythmias 2
• Maintain permissive hypertension per neurology (BP goal <220/120 for 48 hours post-stroke) 2

Await TTE Results:

• Already completed—shows stable EF 40-45%, but worsening valvular disease (moderate AR/AS, moderate MR, new moderate MS)
• Left pleural effusion noted—may contribute to dyspnea
• No acute mechanical complications identified

Antiplatelet Strategy: Critical Decision Point

The most pressing clinical dilemma is antiplatelet/anticoagulation management given competing risks:

• Acute ischemic stroke (right frontal infarct on MRI)
• Known 4mm ACOM aneurysm (bleeding risk)
• Type 2 NSTEMI (thrombotic risk)
• History of GI bleeding
• Recurrent cryptogenic strokes despite Aggrenox

Recommendation: Continue Aggrenox (aspirin-dipyridamole 25-200mg BID) as currently prescribed, but defer final antiplatelet/anticoagulation decision to neurology after TTE shunt study results 2. The 2020 ESC guidelines emphasize that in cryptogenic stroke with cardiac considerations, the etiology must guide therapy 3. If TTE demonstrates PFO or other cardioembolic source, anticoagulation may be warranted despite aneurysm risk. Neurology's suggestion to "discuss switching to anticoagulation following TTE results" is appropriate given recurrent cryptogenic events.

Key consideration: If cardiology requires heparin for NSTEMI management, neurology recommends low-dose infusion without boluses—this is a reasonable compromise, though given type 2 MI etiology and patient's goals, heparin is not indicated 1.

Stroke Management Integration

Acute Stroke Protocol (Per Neurology Recommendations)

Completed/Ongoing:

• MRI confirmed acute right frontal infarct
• CTA negative for large vessel occlusion or high-grade stenosis
• Permissive hypertension protocol (BP <220/120 × 48 hours) 2
• NPO pending swallow evaluation
• Neurochecks Q4 hours
• PT/OT/ST consultations

Pending Workup:

• CT chest/abdomen/pelvis (per tele-neuro for embolic source evaluation)
• TTE with shunt study (ordered—critical for PFO evaluation)
• TSH, HbA1c, lipid panel (ordered)
• Hypercoagulability workup previously unremarkable except elevated Lp(a)

Cerebral Aneurysm Considerations

The 4mm ACOM aneurysm is below typical treatment threshold (most guidelines recommend intervention at ≥7mm for unruptured aneurysms), but it complicates anticoagulation decisions 4. The patient follows neurosurgery—defer aneurysm management decisions to that team. The aneurysm itself is unlikely causing current symptoms but represents significant bleeding risk if aggressive anticoagulation is pursued.

Secondary Prevention Optimization

Lipid Management

• Current: Atorvastatin 40mg + Ezetimibe 10mg daily
• LDL goal <55 mg/dL per cardiology (appropriate for very high-risk patient) 2
• LDL goal <70 mg/dL per neurology (also appropriate)
• Action: Await lipid panel results; if LDL not at goal, consider high-intensity statin (atorvastatin 80mg) given elevated Lp(a) and recurrent vascular events

Heart Failure Management

• Current regimen: Entresto, Toprol, Jardiance (home medications)
• Acute decompensation: Trial Lasix 20mg IV as ordered
• EF 40-45% (HFrEF)—continue guideline-directed medical therapy
• New findings: Worsening valvular disease (moderate AS/AR/MR, new moderate MS) may contribute to decompensation
• Consideration: Valvular disease progression may limit long-term prognosis more than CAD given non-revascularizable coronary disease

Glycemic Control

• Current glucose values: 254,213,214 mg/dL (elevated)
• Await HbA1c results
• Action: Optimize diabetes management—poor control contributes to both cardiovascular and stroke risk

Prognostic Considerations

Short-Term (In-Hospital)

• Type 2 NSTEMI: Lower mortality risk than type 1 MI when managed conservatively 1
• Acute stroke: Neurologically stable with visual field deficits and mild dysarthria
• Decompensated HF: Responsive to diuresis
• Risk factors for complications: Age 77, reduced EF, moderate valvular disease, CKD (eGFR 39), anemia (Hgb 12.9)

Long-Term

• Non-revascularizable CAD with 23% LV scar: Limited by prior viability assessment
• Recurrent cryptogenic strokes: High risk of recurrence—etiology determination critical 3
• Progressive valvular disease: May become symptomatic, but patient's goals preclude intervention
• HFrEF with multiple comorbidities: Guarded prognosis

Given palliative goals, focus should shift toward symptom management, quality of life, and preventing recurrent disabling stroke rather than aggressive cardiac interventions.

What NOT to Do: Common Pitfalls

1. Do not pursue cardiac catheterization given type 2 MI, non-revascularizable disease, and patient's stated goals 1
2. Do not start therapeutic anticoagulation without neurology input given cerebral aneurysm and GI bleeding history
3. Do not aggressively lower blood pressure in acute stroke period—permissive hypertension protocol is appropriate 2
4. Do not discontinue Aggrenox without neurology approval—recurrent cryptogenic strokes suggest current regimen may be inadequate, but abrupt cessation increases stroke risk
5. Do not overlook goals-of-care discussion if clinical deterioration occurs—DNR/I status suggests patient prioritizes comfort over aggressive intervention

Monitoring Plan

• Troponin Q6H until peak and downtrending
• Continuous telemetry until biomarkers stable 2
• Daily clinical assessment for recurrent chest pain, neurologic changes, or HF decompensation
• Neurochecks Q4H with stat head CT for acute changes
• Await pending studies: TTE shunt study, CT CAP, labs (TSH, HbA1c, lipids)

Disposition Planning

• ICU/monitored bed appropriate given NSTEMI and acute stroke 2
• Length of stay: Likely 3-7 days depending on biomarker trajectory, neurologic stability, and swallow evaluation
• Discharge planning: Ensure outpatient neurology, cardiology, and primary care follow-up; optimize medical therapy; PT/OT/ST as needed; consider palliative care consultation for goals-of-care alignment

The cornerstone of this patient's management is respecting her palliative goals while providing excellent supportive care, preventing recurrent stroke through etiology-directed therapy, and optimizing medical management of her multiple comorbidities. 1, 2